Published Date: 13 Mar 2023
New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.
Read Full NewsIn a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?
New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.
A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.
1.
Predicting adult mortality from oral cancer using a machine learning approach.
2.
Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries
3.
The most precise research tools for the deadliest blood cancer have been developed.
4.
Sydney researchers identify new tools to improve cancer diagnosis and treatment.
5.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
3.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
4.
The Role of Alanine Aminotransferase in Liver Health and Disease
5.
The Link Between Being Overweight and Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
4.
Navigating the Complexities of Ph Negative ALL - Part XVI
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation